{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:20:55Z","timestamp":1788009655120,"version":"build-2784847793"},"reference-count":77,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ertan Research and Education Foundation","award":["114069"],"award-info":[{"award-number":["114069"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Inflammatory bowel disease (IBD), encompassing Crohn\u2019s disease (CD) and ulcerative colitis (UC), is a chronic and often debilitating condition requiring complex and individualized management. Over the past few decades, advancements in understanding IBD pathophysiology have led to a transformative shift in therapeutic approaches. This article provides a comprehensive overview of the evolution of IBD treatments, from early symptom-focused therapies to modern biologics, small molecule agents, and emerging treatment strategies. We discuss therapeutic goals centered on achieving clinical remission, endoscopic\/mucosal healing, and enhancing patient quality of life. Additionally, we explore the rationale for the early and personalized use of biologic therapies in moderate-to-severe cases, review the current FDA-approved agents as of 2024, and highlight the advantages and limitations of these treatments. Special attention is given to the evolving role of novel oral therapies, including Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators, and future new directions. This paper aims to guide clinicians in navigating the expanding therapeutic landscape of IBD, emphasizing patient-centered decision-making and addressing ongoing challenges in achieving optimal disease control.<\/jats:p>","DOI":"10.3390\/jcm13237026","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T06:57:54Z","timestamp":1732172274000},"page":"7026","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Optimal Management of Patients with Moderate-to-Severe Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"13","author":[{"given":"Tugrul","family":"Purnak","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University Texas McGovern Medical School, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atilla","family":"Ertan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University Texas McGovern Medical School, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br. Med. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn\u2019s disease with 6-mercaptopurine. A long-term, randomized, double-blind study","volume":"302","author":"Present","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ecco-jcc\/jjw198","article-title":"ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update","volume":"11","author":"Danese","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target","volume":"110","author":"Sandborn","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11894-010-0146-8","article-title":"Mucosal healing in inflammatory bowel disease: Where do we stand?","volume":"12","author":"Ha","year":"2010","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_10","first-page":"2","article-title":"Medical Therapy Update in Crohn\u2019s Disease","volume":"2","year":"2014","journal-title":"SOJ Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG Clinical Guideline: Management of Crohn\u2019s Disease in Adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions","volume":"14","author":"Panes","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ibd.21870","article-title":"Recommendations for the treatment of Crohn\u2019s disease with tumor necrosis factor antagonists: An expert consensus report","volume":"18","author":"Feagan","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Leone, G.M., Mangano, K., Petralia, M.C., Nicoletti, F., and Fagone, P. (2023). Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041630"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: Data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s40259-013-0064-z","article-title":"Pegylation of biological molecules and potential benefits: Pharmacological properties of certolizumab pegol","volume":"28","author":"Pasut","year":"2014","journal-title":"BioDrugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1756284818821266","DOI":"10.1177\/1756284818821266","article-title":"Golimumab in the treatment of ulcerative colitis","volume":"12","author":"Cunningham","year":"2019","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_22","unstructured":"(2024, October 07). Simponi\u2014Accessdata.fda.gov, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125289s0064lbl.pdf."},{"key":"ref_23","first-page":"314","article-title":"IBD: Safety and efficacy of switching to biosimilars in IBD","volume":"13","author":"Leake","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/00365521.2015.1054422","article-title":"Treatment preferences of originator versus biosimilar drugs in Crohn\u2019s disease; discrete choice experiment among gastroenterologists","volume":"51","author":"Baji","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","article-title":"Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation","volume":"14","author":"Schreiber","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/CEG.S293272","article-title":"Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives","volume":"14","author":"Gubatan","year":"2021","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3748\/wjg.v24.i23.2457","article-title":"Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence","volume":"24","author":"Scribano","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13318-022-00804-6","article-title":"Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects","volume":"48","author":"Xie","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/S0016-5085(17)30930-7","article-title":"Sandborn. Fistula Healing in Pivotal Studies of Ustekinumab in Crohn\u2019s Disease","volume":"152","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/archdermatol.2011.161","article-title":"Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: Case report and review of the literature","volume":"147","author":"Gratton","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: Results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"Panaccione","year":"2022","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: A randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn\u2019s Disease","volume":"391","author":"Chapman","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"388","author":"Dubinsky","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study","volume":"165","author":"Allegretti","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_41","unstructured":"Janssen Research & Development LLC (2024, October 07). A Study of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn\u2019s Disease (DUET-CD), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05242471."},{"key":"ref_42","unstructured":"Janssen Research & Development LLC (2024, October 07). A Study of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis (DUET-UC), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05242484."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.55730\/1300-0144.5722","article-title":"Oral small molecule agents in management of ulcerative colitis: Fact or fancy?","volume":"53","author":"Kasapoglu","year":"2023","journal-title":"Turk. J. Med. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1707500","article-title":"Correspondence: Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-World Effectiveness and Safety of Tofacitinib in Patients with Ulcerative Colitis: Systematic Review with Meta-Analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","article-title":"Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study","volume":"21","author":"Straatmijer","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Shehab, M., Hassan, A., Alrashed, F., Abbas, A., Ma, C., Narula, N., Jairath, V., Singh, S., and Bessissow, T. (2024). Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. Inflamm. Bowel Dis., izae163.","DOI":"10.1093\/ibd\/izae163"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: Recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of Upadacitinib in a Randomized Trial of Patients with Active Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1007\/s10620-024-08630-3","article-title":"Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib","volume":"69","author":"Odah","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.12998\/wjcc.v12.i24.5468","article-title":"Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis","volume":"12","author":"Soldera","year":"2024","journal-title":"World J. Clin. Cases"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s40265-022-01762-8","article-title":"Ozanimod: A Review in Ulcerative Colitis","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"104793","DOI":"10.1016\/j.phrs.2020.104793","article-title":"Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology","volume":"156","author":"Jozefczuk","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_59","unstructured":"European Medicines Agency (2024, October 07). (Ozanimod Hydrochloride): EU Summary of Product Characteristics. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20211118153769\/anx_153769_en.pdf."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.cgh.2024.03.042","article-title":"Ozanimod in Patients with Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies","volume":"22","author":"Sands","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Laredo, V., Garcia-Mateo, S., Martinez-Dominguez, S.J., Lopez de la Cruz, J., Gargallo-Puyuelo, C.J., and Gomollon, F. (2023). Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management. Cancers, 15.","DOI":"10.3390\/cancers15030871"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_66","unstructured":"(2022). Efficacy and Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Moderately to Severely Active Ulcerative Colitis: 12-Week Results From the Phase 2 LATTICE-UC Study. Gastroenterol. Hepatol., 18, 6."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ecco-jcc\/jjab232.023","article-title":"A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn\u2019s Disease","volume":"16","author":"Danese","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1053\/j.gastro.2021.08.045","article-title":"PTG-100, an Oral alpha4beta7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis","volume":"161","author":"Sandborn","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sands, B.E., Schreiber, S., Danese, S., Kierkus, J., Abhyankar, B., Choi, M., Soo, C., Wu, Y., Sun, F., and Lee, D. (2023, January 14\u201317). Clinical proof of principle and favorable tolerability profile shown with orally dosed MORF-057 as induction therapy for moderately to severely active ulcerative colitis: Phase 2a EMERALD-1 study results-MP009. Proceedings of the UEGW, Copenhagen, Denmark.","DOI":"10.1093\/ecco-jcc\/jjac190.0040"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"i1202","DOI":"10.1093\/ecco-jcc\/jjad212.0756","article-title":"P626 JNJ-77242113, an oral peptide selectively targeting the IL-23 receptor, demonstrates pharmacodynamic activity in rat and human colon tissue explants following oral dosing","volume":"18","author":"Strawn","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_71","first-page":"0303","article-title":"Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2 [abstract]","volume":"76","author":"Ferris","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1189\/jlb.3RI0315-095R","article-title":"The TNF-family cytokine TL1A: From lymphocyte costimulator to disease co-conspirator","volume":"98","author":"Richard","year":"2015","journal-title":"J. Leucoc. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S2468-1253(22)00233-3","article-title":"ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: A phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension","volume":"7","author":"Vermeire","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e000680","DOI":"10.1136\/bmjgast-2021-000680","article-title":"A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis","volume":"8","author":"Weisel","year":"2021","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/gutjnl-2020-323405","article-title":"Reverse translation approach generates a signature of penetrating fibrosis in Crohn\u2019s disease that is associated with anti-TNF response","volume":"71","author":"Xiong","year":"2022","journal-title":"Gut"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"i162","DOI":"10.1093\/ecco-jcc\/jjac190.0127","article-title":"The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn\u2019s Disease: Phase 2a APOLLO-CD Study Results","volume":"17","author":"Feagan","year":"2023","journal-title":"J. Crohn\u2019s Colitis"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:36:46Z","timestamp":1760114206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":77,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13237026"],"URL":"https:\/\/doi.org\/10.3390\/jcm13237026","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}